Historical AI Consensus
This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.
- Symbol
- RGTI.NASDAQ
- Batch
- 7
- Published
- September 20, 2026
- AI Advisors
- 14
Historical AI Consensus Investment Thesis
Rigetti Computing (RGTI) Stock Forecast and AI Rating
Forecast targets and rating
Published batch rating
SELL ALL
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
SELL ALL$11
-27.5%5-Year
SELL ALL$7.27
-53.9%Published batch insight
Sovereign Quantum Foundry Backing Collides With Severe Valuation Multiple Realities
A high consensus indicates that robust cash reserves and sovereign CHIPS Act backing eliminate near-term insolvency, yet extreme valuation multiples and relentless operating cash burn will force multi-year price compression as commercial enterprise adoption lags speculative expectations.
This analysis preserves the original published batch. Audit published forecasts in full transparency
Sherlock Holmes (Whistleblower), Universal Investor (Polymath), Michael Burry (Vulture), Elon Musk (Visionary), J.P. Morgan (Titan), Superintelligence (Anthropologist), Warren Buffett (Value Purist), Machiavelli (Insider), Ray Dalio (Strategist). Some archetypes run in multiple modes, resulting in 14 advisors total.
Full published thesis
Executive Summary
If you invested $10,000 in Rigetti Computing at the forecast anchor (2026-09-18): $4,611 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 14.00 | -11.16% | -11.16% | Elevated Treasury yields and monetary policy friction trigger multiple contraction across speculative technology equities, dampening initial euphoria surrounding federal funding letters of intent. |
| Q1 2027 | 12.95 | -7.51% | -17.83% | Revenue recognition from international research contracts sparks a tactical relief rally, temporarily offsetting persistent quarterly operating losses and heavy cryogenic packaging expenditures. |
| Q2 2027 | 12.33 | -4.78% | -21.76% | Post-delivery revenue moderation and the finalization of milestone-gated grant terms refocus market attention on underlying operating burn and federal equity warrant dilution. |
| Q3 2027 | 11.43 | -7.32% | -27.48% | Extended commercial enterprise procurement cycles and sluggish cloud compute utilization confirm that near-term gate-model quantum monetization remains confined to specialized academic laboratories. |
| Q4 2027 | 10.76 | -5.83% | -31.71% | Year-end tax-loss rebalancing and ongoing fixed cleanroom overhead pressure valuations, while modular multi-chiplet milestone disclosures provide a technical support floor. |
| Q1 2028 | 10.24 | -4.90% | -35.06% | Disbursement of secondary federal milestone funding and delivery of hybrid supercomputing modules generate constructive headlines, fueling a modest technical and sentiment rebound. |
| Q2 2028 | 9.86 | -3.63% | -37.41% | Rival quantum architectures demonstrate competitive gate fidelity benchmarks, prompting investors to discount long-term transmon commercial market share and pressuring forward sales multiples. |
| Q3 2028 | 9.56 | -3.06% | -39.33% | Updated multi-chip processor benchmarks validate manufacturing feasibility at the captive foundry, though persistent operating losses and capital intensity limit sustained upward momentum. |
| Q4 2028 | 9.11 | -4.69% | -42.17% | Anticipation of fresh equity issuance to fund extended fabrication roadmaps introduces dilution overhang, reinforcing the downward repricing of long-duration speculative cash flows. |
| Q1 2029 | 8.68 | -4.79% | -44.94% | Annual financial reporting reveals that revenue growth remains insufficient to cover escalating R&D overhead, puncturing expectations of near-term self-sustaining commercial operations. |
| Q2 2029 | 8.64 | -0.43% | -45.18% | Sovereign defense research renewals and allied national laboratory purchase orders provide non-dilutive capital, generating a transient relief rally among institutional quantum specialists. |
| Q3 2029 | 8.22 | -4.90% | -47.86% | Enterprise IT budgets consolidate around commercial generative artificial intelligence infrastructure, starving exploratory quantum algorithmic pilots of corporate discretionary capital. |
| Q4 2029 | 7.87 | -4.19% | -50.05% | Valuation multiples across speculative deep-tech peers compress toward historical hardware equipment benchmarks, reducing the premium attached to unproven fault-tolerant roadmaps. |
| Q1 2030 | 7.91 | +0.46% | -49.82% | Recognized hardware deliveries for hybrid classical-quantum computing clusters stabilize top-line performance, encouraging value-oriented technology allocators to establish long-term positions. |
| Q2 2030 | 7.68 | -2.91% | -51.29% | Capital expenditure requirements for next-generation cryogenic facilities and automated chip packaging lines accelerate cash consumption, triggering renewed multiple compression. |
| Q3 2030 | 7.39 | -3.80% | -53.13% | Cloud hyperscalers expand internal quantum software abstraction layers, limiting third-party computing access revenue and reinforcing the company's positioning as a component fabricator. |
| Q4 2030 | 7.33 | -0.76% | -53.49% | Year-end portfolio rebalancing meets the announcement of a strategic sovereign testbed expansion, stabilizing equity quotes near tangible balance-sheet backing. |
| Q1 2031 | 7.28 | -0.75% | -53.84% | Full-year results confirm steady top-line expansion into the tens of millions, though cumulative operational deficits preserve conservative institutional valuation models. |
| Q2 2031 | 7.31 | +0.50% | -53.60% | Improved packaging yields at the captive fabrication facility reduce unit manufacturing costs, narrowing quarterly operating losses and supporting steady consolidation. |
| Q3 2031 | 7.27 | -0.62% | -53.89% | The five-year forecast concludes with market pricing fully transitioned from speculative platform monopoly to a valued, sovereign-backed niche quantum hardware contractor. |
The investment thesis reflects a pronounced divergence between corporate solvency and equity valuation. A balance sheet holding over five hundred and forty million dollars in liquid assets, alongside a hundred-million-dollar milestone-gated federal CHIPS Act award, effectively eliminates structural bankruptcy risk. However, with trailing twelve-month revenue near thirteen million dollars against an annual free cash outflow approaching ninety million dollars, current enterprise pricing discounts multi-decade commercial quantum supremacy today. Under a restrictive discount-rate environment, the multi-hundred-fold price-to-sales multiple is mathematically indefensible without exponential recurring software monetization.
Key insights
- Sovereign backing establishes a durable valuation floor, transforming operations into an indispensable national defense research asset while dilutive warrants cap equity upside.
- Cryogenic and thermodynamic scaling constraints in superconducting transmons prolong the fault-tolerant roadmap, keeping enterprise usage confined to exploratory laboratory pilot projects.
- Sustained multiple compression toward specialized semiconductor equipment benchmarks will overpower operational top-line progress, driving an orderly multi-year equity repricing.
The company has plenty of cash and strong government backing through defense contracts and federal funding, meaning it will not go out of business anytime soon. However, its stock price is priced as if quantum computers are already taking over the world. In reality, it brings in modest revenue while spending heavily on advanced cleanroom facilities and cryogenic equipment, meaning the business will take many years to become profitable.
Key insights
- Over five hundred million dollars in net cash provides years of runway to develop advanced quantum processors.
- The stock trades at an extreme valuation that must shrink as investors demand real commercial profits.
- Government grants keep research alive but require issuing more shares, which reduces per-share value for existing investors.
Deep Dive
Prevailing market sentiment views the company as an indispensable pure-play national champion destined to dominate sovereign quantum computing. Retail momentum and speculative analysts anchor heavily on top-line revenue spikes, federal CHIPS Act endorsements, and expanding on-premises hardware shipments. The crowd treats developmental milestone announcements as proof of imminent commercial quantum advantage, assuming federal patronage effortlessly bridges the multi-year chasm to profitability.